Tyr189
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr189  -  BLNK (human)

Site Information
VEDNDENyIHPtESS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447717

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 1 ) , immunoprecipitation ( 1 ) , mutation of modification site ( 1 ) , peptide sequencing ( 1 ) , phospho-antibody ( 1 ) , phosphopeptide mapping ( 1 ) , western blotting ( 1 )
Disease tissue studied:
lymphoma ( 1 ) , B cell lymphoma ( 1 ) , Burkitt's lymphoma ( 1 )
Relevant cell line - cell type - tissue:
Daudi (B lymphocyte) ( 1 ) , DT40 (B lymphocyte) ( 1 )

Upstream Regulation
Kinases, in vitro:
Syk (human) ( 1 )
Treatments:
antigenic stimulation ( 1 )

Downstream Regulation
Effects of modification on BLNK:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
transcription, altered ( 1 )
Induce interaction with:
Btk (human) ( 1 ) , NCK2 (human) ( 1 ) , PLCG1 (human) ( 1 ) , VAV1 (human) ( 1 )

References 

1

Chiu CW, et al. (2002) BLNK: molecular scaffolding through 'cis'-mediated organization of signaling proteins. EMBO J 21, 6461-72
12456653   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.